NCT01270516View on ClinicalTrials.gov

Effect of EPA and HMB on Strength in ICU Patients

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions
Muscle Weakness
Interventions
DRUG

HMB, hydroxymethylbutyrate

Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days

DRUG

EPA, eicosapentaenoic acid

EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days

DRUG

Saline

Control

Trial Locations (1)

40536

Chandler Hospital, Lexington

All Listed Sponsors
lead

Gerald Supinski

OTHER

NCT01270516 - Effect of EPA and HMB on Strength in ICU Patients | Biotech Hunter | Biotech Hunter